IL-17

Richard Conway RichardPAConway
3 years 11 months ago
Dr Elliott presenting on US assessment of enthesitis with TNFi vs secukinumab. Surprisingly TNFi showed a more marked decrease in US enthesitis. Abstr#1356 #ACR21 @RheumNow https://t.co/XXgYMgkMyP


Richard Conway RichardPAConway
3 years 11 months ago
Effect of BMI on PRO treatment response in PsA. Increasing BMI associated with lower response. More pronounced in TNFi than IL-17 or JAKi. Abstr#1327 #ACR21 @RheumNow https://t.co/qhgVlW72uM


Mrinalini Dey DrMiniDey
3 years 11 months ago
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression.
#Abs0909 #ACR21 @RheumNow
https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh


TheDaoIndex KDAO2011
3 years 11 months ago
@JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.